The Moroccan government has announced that international company Recipharm will be withdrawing from its partnership with MARBIO, a vaccine platform established in 2021. According to a statement released by the Mohammed VI Investment Fund, Recipharm will be transferring its 10% stake in MARBIO to the fund. This move marks a new phase in the development of MARBIO, which was established to enhance Morocco's healthcare sovereignty and provide the country with industrial and technological capabilities in vaccine and bioproduct manufacturing.
The partnership between Morocco, Recipharm, and BAB Consortium was launched in September 2021 under the leadership of King Mohammed VI. The collaboration aimed to bolster Morocco's healthcare sector and provide the country with the necessary capabilities to develop and manufacture vaccines and bioproducts. Over the past five years, MARBIO has undergone significant structural development, including the establishment of an industrial site in Benslimane dedicated to sterile packaging and filling of vaccines and bioproducts.
MARBIO's development has been supported by its partners, including Recipharm, which has provided technical, industrial, operational, and regulatory expertise. The company has acquired the necessary capabilities to gradually develop its activities and has become a major player in Morocco's healthcare sector. The Mohammed VI Investment Fund's acquisition of Recipharm's stake in MARBIO is expected to further support the company's growth and development.
The agreement between the parties was signed on September 21, 2026, and outlines the terms of Recipharm's withdrawal and the transfer of its stake to the Mohammed VI Investment Fund. The agreement also includes measures to ensure a smooth transition and continuity of operations at MARBIO. The Mohammed VI Investment Fund's involvement in MARBIO is part of its mission to stimulate productive investment and mobilize capital to support Morocco's strategic priorities.
The withdrawal of Recipharm from MARBIO and the acquisition of its stake by the Mohammed VI Investment Fund are expected to have a positive impact on the company's development and growth. The new partnership structure is expected to enhance MARBIO's national roots and create conditions for sustainable growth and long-term industrial development. MARBIO will continue to contribute to Morocco's healthcare sovereignty and is expected to play a major role in securing healthcare supply chains in Africa.
MARBIO was established in 2021 with an initial capital of 1.4 billion dirhams and is headquartered in Casablanca. The company specializes in the development and contract manufacturing of vaccines with an international focus. The Mohammed VI Investment Fund, which has a social capital of 15 billion dirhams, is a sovereign wealth fund that finances and supports structured projects and companies in priority sectors.
Recipharm is a leading international company in the development and contract manufacturing of vaccines, with operations in several countries, including Germany, Spain, the United States, France, India, Italy, Portugal, and Sweden. The company's withdrawal from MARBIO marks a new phase in the development of the vaccine platform, which is expected to continue playing a major role in Morocco's healthcare sector.
Key points
- Recipharm to withdraw from MARBIO vaccine platform, transferring 10% stake to Mohammed VI Investment Fund.
- MARBIO to continue developing and manufacturing vaccines and bioproducts with support of new partnership structure.
- Mohammed VI Investment Fund to support MARBIO's growth and development, enhancing Morocco's healthcare sovereignty.
